Crossmark

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15

Crossref DOI link: https://doi.org/10.1186/s40425-019-0507-2

Published Online: 2019-01-22

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yao, Junlin

Ly, Dalam

Dervovic, Dzana

Fang, Linan

Lee, Jong Bok

Kang, Hyeonjeong

Wang, Yu-Hui

Pham, Nhu-An

Pan, Hongming

Tsao, Ming-Sound

Zhang, Li
Funding

Funding for this research was provided by:

Canadian Institutes of Health Research

Ontario Research Fund Research Excellence (RE-03-020)
More Information

Article History

Received: 23 July 2018

Accepted: 13 January 2019

First Online: 22 January 2019

Ethics approval and consent to participate

: Blood samples from volunteers were collected with informed consent using a protocol (#05–0221-T) approved by the University Health Network (UHN) Research Ethics Board. Animal studies were approved by UHN Animal Care Committee (AUP # 741.34) and carried out in accordance with the Canadian Council on Animal Care Guidelines.

: Not applicable

: Li Zhang is one of the inventors on 7 DNT cell technology-related patents and serves as a scientific consultant for WYZE BIOTECH Co. Ltd. Other authors declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.